Auflistung nach Autor "Grischke, Eva-Maria"

Beckert, Stefan; Struller, Florian; Grischke, Eva-Maria; Glatzle, Jörg; Zieker, Derek Anthony Gerald; Königsrainer, Alfred; Königsrainer, Ingmar (2016)

Clinical Significance of PIK3CA and ESR1 Mutations in Circulating Tumor DNA: Analysis from the MONARCH 2 Study of Abemaciclib plus Fulvestrant

Grischke, Eva-Maria (2022)

CNS metastases in breast cancer patients: prognostic implications of tumor subtype

Staebler, Annette; Bachmann, Cornelia; Fend, Falko; Schittenhelm, Jens Florian; Wallwiener, Diethelm; Grischke, Eva-Maria; Schmidt, S. (2015)

CNS metastases of breast cancer show discordant immunohistochemical phenotype compared to primary

Grischke, Eva-Maria; Bachmann, Cornelia; Fehm, Tanja; Wallwiener, Diethelm; Staebler, Annette; Schittenhelm, Jens Florian (2013)

Comparison of Biosimilar Trastuzumab ABP 980 with Reference Trastuzumab in Neoadjuvant Therapy for HER2-positive Breast Cancer - an Analysis of a Large University Breast Cancer Centre

Matovina, Sabine; Engler, Tobias; Grischke, Eva-Maria; Staebler, Annette; Hahn, Markus; Volmer, Léa; Müller, Heike; Brucker, Sara; Hartkopf, Andreas (2023)

Comparison of Neoadjuvant Nab-Paclitaxe plus Carboplatin vs Nab-Paclitaxe plus Gemcitabine in Triple-Negative Breast Cancer : Randomized WSG-ADAPT-TN Trial Results

Grischke, Eva-Maria (2018)

Contralateral prophylactic mastectomy : Breast cancer patients from BRCA1/2 negative high risk families

Grischke, Eva-Maria (2013)

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in recurrent epithelial ovarian cancer with peritoneal metastases: a single centre experience

Horvath, Philipp; Struller, Florian; Grischke, Eva-Maria; Wallwiener, Diethelm; Beckert, Stefan; Königsrainer, Ingmar; Königsrainer, Alfred (2014)

De-escalated Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer (TNBC): Impact of Molecular Markers and Final Survival Analysis of the WSG-ADAPT-TN Trial

Grischke, Eva-Maria (2022)

De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR-): survival outcomes from a multicentre, open-label, randomised, phase 2 trial

Grischke, Eva-Maria (2022)

De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR- phase II trial: efficacy, safety, and predictive markers for 12 weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab +/- weekly paclitaxel

Grischke, Eva-Maria (2017)